Variability in Plasma Lipids Between Intensive Statin Therapy and Conventional-Dose Statins Combined with Ezetimibe Therapy in Patients with Coronary Atherosclerosis Disease
-
- Jin Jinhua
- Department of Cardiology, Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University Key Laboratory of Cardiovascular Intervention and Regenerative Medicine of Zhejiang Province
-
- Shan Liwen
- Department of Cardiology, Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University Key Laboratory of Cardiovascular Intervention and Regenerative Medicine of Zhejiang Province
-
- Wang Manjun
- Department of Cardiology, Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University Key Laboratory of Cardiovascular Intervention and Regenerative Medicine of Zhejiang Province
-
- Liu Lu
- Department of Cardiology, Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University Key Laboratory of Cardiovascular Intervention and Regenerative Medicine of Zhejiang Province
-
- Xu Tian
- Ningbo First Hospital
-
- Li Duanbin
- Department of Cardiology, Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University Key Laboratory of Cardiovascular Intervention and Regenerative Medicine of Zhejiang Province
-
- Chen Zhezhe
- Department of Cardiology, Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University Key Laboratory of Cardiovascular Intervention and Regenerative Medicine of Zhejiang Province
-
- Liu Xianglan
- Department of Cardiology, Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University Key Laboratory of Cardiovascular Intervention and Regenerative Medicine of Zhejiang Province
-
- Zhang Wenbin
- Department of Cardiology, Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University Key Laboratory of Cardiovascular Intervention and Regenerative Medicine of Zhejiang Province
-
- Li Ya
- Department of Cardiology, Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University Key Laboratory of Cardiovascular Intervention and Regenerative Medicine of Zhejiang Province
抄録
<p>Dyslipidemia has been widely recognized as a significant risk factor for coronary atherosclerosis disease (CAD). In fact, lipid variability has emerged as a more reliable predictor of cardiovascular events. In this study, we aimed to examine the variability in plasma lipids under two different lipid-lowering regimens (intensive statin therapy versus the combination of conventional-dose statins with ezetimibe). In total, we have retrospectively examined 1275 patients with CAD from January 2009 to April 2019 and divided them into two groups: intensive statin group and conventional-dose statins combined with ezetimibe group. All patients were followed up for at least 1 year. Lipid variability was verified by standard deviation (SD), coefficient of variation (CV), and variability independent of mean (VIM) triple methods. Multiple linear regression and subgroup analyses were performed. In the overall participants, the mean age was 62.3 ± 10.4 years old, and 72.8% were male. Multivariate linear regression analysis indicated that the intensive statin group had lower variability in terms of total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C), and non-high-density lipoprotein cholesterol (non-HDL-C) in all SD, CV, and VIM triple methods than statins combined with ezetimibe group (P for all <0.05). Similar results were established in the subgroup analyses based on atorvastatin or rosuvastatin, diabetes mellitus or not, and hypertension or not (P for all < 0.05). Thus, we can conclude that intensive statin therapy could contribute in lowering lipid variability than conventional-dose statins combined with ezetimibe therapy among patients with CAD.</p>
収録刊行物
-
- International Heart Journal
-
International Heart Journal 64 (5), 807-815, 2023-09-30
一般社団法人 インターナショナル・ハート・ジャーナル刊行会